

Resource Summary Report

Generated by NIF on Sep 5, 2026

InVivoMab anti-mouse IFNAR-1

RRID:AB_2687723

Type: Antibody

Proper Citation

(Bio X Cell Cat# BE0241, RRID:AB_2687723)

Antibody Information

URL: http://antibodyregistry.org/AB_2687723

Proper Citation: (Bio X Cell Cat# BE0241, RRID:AB_2687723)

Target Antigen: IFNAR-1

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: in vivo IFNAR-1 blockade, in vitro IFNAR-1 blockade

Antibody Name: InVivoMab anti-mouse IFNAR-1

Description: This monoclonal targets IFNAR-1

Target Organism: mouse

Clone ID: clone MAR1-5A3

Antibody ID: AB_2687723

Vendor: Bio X Cell

Catalog Number: BE0241

Alternative Catalog Numbers: BE0241-50MG, BE0241-25MG, BE0241-5MG, BE0241-1MG, BE0241-100MG

Record Creation Time: 20260114T193148+0000

Record Last Update: 20260828T165341+0000

Ratings and Alerts

No rating or validation information has been found for InVivoMab anti-mouse IFNAR-1.

No alerts have been found for InVivoMab anti-mouse IFNAR-1.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 71 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Burchett R, et al. (2026) A Universal Boosting Strategy for Adoptive T-cell Therapy Using a Paired Vaccine/Chimeric Antigen Receptor. *Cancer immunology research*, 14(2), 261.

Bizzotto M, et al. (2026) Maternal-fetal type I interferon signaling drives TREM2 dysregulation and synaptic dysfunction in neurodevelopmental disorders. *Neuron*.

Shaw SC, et al. (2026) Type I interferon signaling in hematopoietic cells impairs neutrophil antibacterial function in the middle ear during viral co-infection. *Cell reports. Medicine*, 7(6), 102846.

Zhang J, et al. (2026) Mrgpra2+ neutrophils integrate infection-derived signals to trigger NET-mediated antimicrobial defense in bone marrow. *Cell reports*, 45(7), 117579.

Marco S, et al. (2026) Radiotherapy synergizes with an inducible AAV-based immunotherapy platform to program local and systemic antitumor immunity. *Cancer cell*, 44(5), 995.

Dunphy G, et al. (2026) A type I interferon-mitochondrial axis regulates efferocytosis and interferon-stimulated gene induction in macrophages. *Immunity*, 59(2), 306.

Yu J, et al. (2026) 6-Hydroxydopamine promotes antitumor immunity through macrophage remodeling beyond sympathetic ablation. *Neuron*, 114(14), 2532.

Cervantes Rincón T, et al. (2026) Analysis of West Nile disease convalescents identifies human monoclonal antibodies protective against West Nile and related orthoflaviviruses. *Immunity*, 59(7), 2015.

Gago da Graça C, et al. (2026) B cell-derived type I interferon sustains T cell functionality upon strong TCR stimulation during chronic infection. *Immunity*.

Kurt-Jones EA, et al. (2025) Interferon-epsilon, an estrogen-induced type I interferon, is uniquely exploited by *Neisseria gonorrhoeae* via effects on sialic acid metabolism. *Cell host & microbe*, 33(7), 1133.

Eislmayr KD, et al. (2025) Macrophages orchestrate elimination of *Shigella* from the intestinal epithelial cell niche via TLR-induced IL-12 and IFN-?. *Cell host & microbe*, 33(9),

1535.

Chua YC, et al. (2025) Mechanistic insight into the induction of liver tissue-resident memory CD8⁺ T cells by glycolipid-peptide vaccination. *Cell reports*, 44(2), 115295.

Zhang S, et al. (2025) p57 increases immunotherapy efficacy by promoting cGAS-STING-mediated innate sensing in hepatocellular carcinoma. *Cell reports*, 45(1), 116769.

Castañó D, et al. (2025) Distinct components of mRNA vaccines cooperate to instruct efficient germinal center responses. *Cell*, 188(26), 7461.

Álvarez-Prado ÁF, et al. (2025) Cancer cell and microenvironmental rewiring by ADAR1 loss impairs glioblastoma tumor growth and extends survival. *Cell reports*, 44(9), 116151.

Wang Q, et al. (2025) ZBP1 pathway promotes tumor immunogenicity in the combination of anti-HER2 therapy and epigenetic therapy. *Cell reports*, 44(10), 116314.

Soliman N, et al. (2025) Targeting Intracellular Innate RNA-Sensing Systems Overcomes Resistance to CAR T-cell Therapy in Solid Tumors. *Cancer research*, 85(14), 2679.

Valvo VM, et al. (2025) Olaparib and Radiotherapy Induce Type I Interferon- and CD8⁺ T Cell-Dependent Sensitization to Immunotherapy in Pancreatic Cancer. *Molecular cancer therapeutics*, 24(6), 843.

Peng X, et al. (2025) Virus envelope glycoprotein targeting bispecific T cell engager protects mice from lethal severe fever with thrombocytopenia virus infection. *Cell reports. Medicine*, 6(11), 102458.

Guo C, et al. (2025) In situ extended immune activation instantly after tumor resection by oncolytic virus controls postoperative tumor recurrence. *Cell reports. Medicine*, 6(10), 102399.